Eczema (dermatitis) refers to inflammatory skin conditions characterized by itch, redness, and rash, with symptom severity varying by subtype and chronicity. Atopic dermatitis is the most common form and often begins in childhood. Clinical burden can range from localized lesions to widespread recurrent disease.
A mouse study identified **TRPV4** as part of the neural feedback system that tells the brain when scratching has been sufficient. The findings suggest broadly blocking TRPV4 may not be the solution for chronic itch.
Slow up-dosing peanut OIT enabled 82% of toddlers to tolerate 3.5 peanuts after treatment. Low-dose OIT was safe in preschoolers with single or multiple food allergies. Allergist guidance on anxiety was linked to reduced caregiver worry.
AI-powered drugmaker Earendil Labs secured $787 million to advance biologics for autoimmune diseases and cancer, while Immunic locked in up to $400 million to fund Phase 3 trials of its multiple sclerosis therapy.
Pfizer's tilrekimig met its primary endpoint in a mid-stage eczema trial and will advance to late-stage testing. Separately, oral remibrutinib demonstrated rapid efficacy in treating peanut allergy in a phase II study.
More than 16,000 dermatology trials were completed, ongoing, or planned by the end of 2025, with the Asia-Pacific region experiencing a nearly five-fold increase over the past decade. The field now accounts for around 8,000 trials in Asia-Pacific alone, matching North America and Europe combined.
Regeneron has consistently increased revenue over 35 years with blockbuster products like Dupixent and Eylea HD, while maintaining over a dozen phase 3 clinical trial candidates across multiple therapeutic areas.
Sanofi replaced CEO Paul Hudson with Belén Garijo from Merck KGaA after a stalled turnaround. The company faces pressure to develop drugs to replace blockbuster Dupixent and navigate U.S. vaccine skepticism.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07599813 |
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis |
RECRUITING | PHASE2 |
| NCT07583121 |
Impact of a Daily Application of an Omega-3 Monoglycerides Based Serum and Cream on the Skin Microbiota |
NOT_YET_RECRUITING | NA |
| NCT07569172 |
Improved Child Nutrition and Development Through Social Transfers |
NOT_YET_RECRUITING | NA |
| NCT07537751 |
Crisaborole vs Fluticasone Propionate in Mild to Moderate Atopic Dermatitis |
COMPLETED | NA |
| NCT07481019 |
A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology |
NOT_YET_RECRUITING | NA |
| NCT07463079 |
Clinical Evaluation of a Soothing Moisturizing Lotion in Individuals With Atopic Eczema |
RECRUITING | NA |
| NCT07453602 |
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 |
RECRUITING | PHASE1 |
| NCT07447063 |
The Impact of Dietary Salt on the Severity of Eczema |
NOT_YET_RECRUITING | PHASE4 |
| NCT07441395 |
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD |
RECRUITING | PHASE2 |
| NCT07367932 |
Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE4 |
